Department of Neuro-Oncology, Dana Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts, USA.
Pediatr Blood Cancer. 2013 Feb;60(2):332-5. doi: 10.1002/pbc.24311. Epub 2012 Sep 19.
Surgery alone is curative for most children with localized MYCN-non-amplified neuroblastoma. However, 10-15% will develop recurrent loco-regional disease, and very rarely, patients will relapse metastatically. Currently, it is not possible to predict which child with localized, MYCN-non-amplified neuroblastoma will develop disseminated disease. We report two children who presented with favorable biology, localized neuroblastoma and subsequently relapsed with metastatic disease after treatment with surgery. Whole-genome DNA copy number analyses performed on the diagnostic tumors identified 15 (case 1) and 8 (case 2) segmental chromosomal alterations. Further analysis of the prognostic value of whole-genome analysis in children with localized neuroblastoma is warranted.
手术单独适用于大多数局限性 MYCN 非扩增神经母细胞瘤患儿。然而，仍有 10-15%的患儿会出现局部复发病灶，极少数患儿会出现远处转移复发。目前，尚无法预测局限性、MYCN 非扩增神经母细胞瘤患儿中哪些会出现播散性疾病。我们报告了两例具有良好生物学特征的局限性神经母细胞瘤患儿，他们在接受手术治疗后出现了转移性疾病复发。对诊断性肿瘤进行的全基因组 DNA 拷贝数分析分别确定了 15 个（病例 1）和 8 个（病例 2）片段性染色体改变。有必要进一步分析全基因组分析在局限性神经母细胞瘤患儿中的预后价值。
